Real-life experiences with CAR T-cell therapy with idecabtagene vicleucel (ide-cel) for triple-class exposed relapsed/refractory multiple myeloma patients

被引：0

作者：

Dilara Akhoundova Sanoyan

Katja Seipel

Ulrike Bacher

Marie-Noelle Kronig

Naomi Porret

Gertrud Wiedemann

Michael Daskalakis

Thomas Pabst

机构：

[1] Inselspital,Department of Medical Oncology

[2] University Hospital of Bern,Department for Biomedical Research

[3] Center for Hemato-Oncology; University Cancer Center,Department of Hematology and Central Hematology Laboratory

[4] University of Bern,Clinical Genomics Lab

[5] Inselspital,undefined

[6] Bern University Hospital,undefined

[7] University of Bern,undefined

[8] Inselspital,undefined

[9] University Hospital of Bern,undefined

来源：

BMC Cancer | / 23卷

关键词：

Myeloma; CAR-T; Relapsed; Outcome; Ide-cel;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

共 50 条

[21] External Control Analysis for KarMMa-3: Idecabtagene Vicleucel (ide-cel) vs Real-World Standard of Care (RW SoC; Connect MM) for Triple-Class Exposed (TCE) Relapsed/Refractory Multiple Myeloma (RRMM)
Jagannath, Sundar
Campbell, Harlan
Park, Julie
Chen, Jenny
Towle, Kevin
Cope, Shannon
Durie, Brian
Lee, Hans
Ailawadhi, Sikander
Abonour, Rafat
Rifkin, Robert
Terebelo, Howard
Narang, Mohit
Gasparetto, Cristina
Toomey, Kathleen
Hardin, James
Marshall, Thomas
Yu, Edward
Liu, Liang
Dhanda, Devender
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S59 - S60
[22] Idecabtagene vicleucel (ide-cel; bb2121); a BCMA-directed CAR T cell therapy; for the treatment of patients with relapsed and refractory multiple myeloma (RRMM): updated results from KarMMa
Einsele, Hermann
Anderson, Larry D., Jr.
Shah, Nina
Jagannath, Sundar
Berdeja, Jesus
Lonial, Sagar
Raje, Noopur
Siegel, David S.
Lin, Yi
Moreau, Philippe
Yakoub-Agha, Ibrahim
Delforge, Michel
Goldschmidt, Hartmut
Weisel, Katja
Cavo, Michele
Reece, Donna
Rambaldi, Alessandro
Truppel-Hartmann, Anna
Patel, Payal
Huang, Liping
Campbell, Timothy B.
Hege, Kristen
San-Miguel, Jesus
Munshi, Nikhil C.
Oriol, Albert
ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 173 - 173
[23] Idecabtagene vicleucel (ide-cel) vs standard regimens in patients with triple-class-exposed (TCE) relapsed and refractory multiple myeloma (RRMM): KarMMa-3 subgroup analysis by prior lines of therapy
Manier, Salomon
Rodriguez-Otero, Paula
Mateos, Maria-Victoria
Einsele, Hermann
Bahlis, Nizar
Munshi, Nikhil
Ailawadhi, Sikander
Arnulf, Bertrand
Nooka, Ajay
Vij, Ravi
Abrahamsen, Ingerid Weum
Broijl, Annemiek
Jagannath, Sundar
Benjamin, Reuben
Gergis, Usama
Sborov, Douglas
Iida, Shinsuke
Truppel-Hartmann, Anna
Yang, Zhihong
Bhatnagar, Rashmi
Piasecki, Julia
Felten, Jasper
Caia, Andrea
Cook, Mark
Baz, Rachid
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S50 - S51
[24] Idecabtagene Vicleucel (ide-cel) in Patients (pts) with Triple-Class-Exposed (TCE) Relapsed and Refractory Multiple Myeloma (RRMM): the 5-year Follow-Up Analysis from KarMMa
Anderson, Larry
San-Miguel, Jesus
Martin, Thomas
Jagannath, Sundar
Berdeja, Jesus G.
Lonial, Sagar
Raje, Noopur
Lin, Yi
Siegel, David
Oriol, Albert
Moreau, Philippe
Yakoub-Agha, Ibrahim
Ishida, Tadao
Truppel-Hartmann, Anna
Chaudhry, Maria
Masciulli, Arianna
Peeramsetti, Sharavi
Wu, Fan
Shamsuzzaman, Md
Thompson, Ethan
Martin, Nathan
Campbell, Timothy
Munshi, Nikhil
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S81 - S82
[25] French Early Nationwide Idecabtagene Vicleucel (Ide-Cel) Chimeric Antigen Receptor (CAR) T-Cell Therapy Experience in Patients with Relapsed/Refractory Multiple Myeloma (FENIX): An IFM Study from the Descar-T Registry
Ferment, Benoit
Lambert, Jerome
Caillot, Denis
Lafon, Ingrid
Karlin, Lionel
Lazareth, Anne
Touzeau, Cyrille
Leleu, Xavier
Moya, Niels
Harel, Stephanie
Perrot, Aurore
Bories, Pierre
Vincent, Laure
Lamure, Sylvain
Mohty, Mohamad
Malard, Florent
Manier, Salomon
Yakoub-Agha, Ibrahim
Stoppa, Anne-Marie
Brisou, Gabriel
Decaux, Olivier
Houot, Roch
Le Gouill, Steven
Facon, Thierry
Avet-Loiseau, Herve
Moreau, Philippe
Arnulf, Bertrand
BLOOD, 2022, 140 : 4668 - 4670
[26] Efficacy of Idecabtagene Vicleucel (ide-cel) in Patients with Relapsed/Refractory Multiple Myeloma and Prior Central Nervous System Manifestation: A Retrospective Real-World Analysis
Maulhardt, Markus
Berning, Philipp
Hanoun, Christine
Boyadzhiev, Hristo
Albici, Anca Maria
Janjetovic, Snjezana
Saidy, Anna Ossami
Call, Simon
Schub, Natalie
Aydilek, Enver
Daskalakis, Michael
Jung, Wolfram
Hasenkamp, Justin
Krekeler, Carolin
Khandanpour, Cyrus
Bacher, Ulrike
Reinhardt, Hans Christian
Lenz, Georg
Stoelzel, Friedrich
Wulf, Gerald
Pabst, Thomas
von Tresckow, Bastian
Shumilov, Evgenii
BLOOD, 2024, 144 : 4760 - 4760
[27] COST-EFFECTIVENESS OF TALQUETAMAB-TGVS VS IDECABTAGENE VICLEUCEL FOR TRIPLE-CLASS EXPOSED RELAPSED OR REFRACTORY MULTIPLE MYELOMA
Rong, R.
Tang, T.
Shi, L.
VALUE IN HEALTH, 2024, 27 (06) : S10 - S10
[28] A Matching-Adjusted Indirect Comparison of Efficacy Outcomes for Idecabtagene Vicleucel (ide-cel, bb2121), a Bcma-Directed CAR T Cell Therapy Versus Conventional Care in Triple-Class-Exposed Relapsed and Refractory Multiple Myeloma
Shah, Nina
Ayers, Dieter
Davies, Faith E.
Cope, Shannon
Mojebi, Ali
Parikh, Kejal
Dhanda, Devender
Hari, Parameswaran
Patel, Payal
Huang, Liping
Hege, Kristen
Dhanasiri, Sujith
BLOOD, 2020, 136
[29] Bendamustine Lymphodepletion (LD) Prior to Idecabtagene Vicleucel (Ide-cel) Is Associated with Inferior Outcomes in Relapsed Refractory Multiple Myeloma (RRMM)
Ravi, Gayathri
Bal, Susan
Godby, Kelly
Giri, Smith
Hebert, Courtney
Parekh, Binita
Steele, JoAnn
Brown, Jessica
Langley, Kathy
Costa, Luciano
BLOOD, 2023, 142
[30] Matching-adjusted indirect comparison of efficacy outcomes for Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-directed CAR T cell therapy, versus conventional care in triple-class-exposed relapsed and refractory multiple myeloma
Goldschmidt, H.
Shah, N.
Ayers, D.
Davies, F.
Cope, S.
Mojebi, A.
Dhanda, D.
Hari, P.
Patel, P.
Huang, L.
Hege, K.
Dhanasiri, S.
ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 205 - 206

← 1 2 3 4 5 →